Skip to content

CG Oncology

US · CGON #1929 by market cap Listed 2024
79.47 -2.43 -2.97%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • Total institutional ownership fell 2.1 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
116.21% -2.15pp
Institutions
307
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund61.76%
VC/PE Fund26.59%
Hedge Fund18.71%
Public Company4.89%
Private Company3.18%
Individual/Insider0.91%
Government Pension Fund0.45%
Endowment Fund0.33%
Insurance Company0.29%

Top holders as of 2026-06-30

T. Rowe Price Group, Inc. 11.67% · 10.42M sh
RTW Investments, LP 9.53% · 8.51M sh
Decheng Capital LLC 7.13% · 6.37M sh
BlackRock 7.11% · 6.35M sh
Wellington Management Group 5.96% · 5.32M sh
Longitude Capital Management Co., LLC 5.22% · 4.66M sh
FMR 5.14% · 4.59M sh
TCG Crossover Management, LLC 4.11% · 3.67M sh
Vanguard Capital Management, LLC 4.00% · 3.57M sh
ORI Capital 3.94% · 3.49M sh
Vanguard Portfolio Management, LLC 3.94% · 3.52M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 15 buys · 35 sells

NameRoleStake
Hong Fang Song Former Independent Director 0.69%
Arthur Kuan Chairperson & CEO 0.22%
Corleen Roche Former Chief Financial Officer 0.00%
Vijay Kasturi Chief Medical Officer 0.00%
Leonard Post Lead Independent Director --
James DeTore Chief Financial Officer --
Victor Tong Independent Director --
Ambaw Bellete Former Chief Operating Officer --
Susan Graf Independent Director --
ORI Capital -- --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-14 Leonard Post Lead Independent Director Intent to Sell (Form 144) -3,000 $61.84
2026-10-14 Leonard Post Lead Independent Director Derivative Exercise and Sale -1,000 $0.60–62.48
2026-10-14 Isabel Kalofonos Chief Commercial Officer Other Derivative Acquisition +92,000 $61.86
2026-09-20 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -30,787 $76.01
2026-09-16 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -6,532 $76.50
2026-09-14 Leonard Post Lead Independent Director Derivative Exercise and Sale -1,000 $0.60–72.98
2026-09-10 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -826 $75.00
2026-09-01 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -29,630 $77.61
2026-08-30 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -50,000 $75.51
2026-08-26 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -5,789 $79.39
2026-08-24 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -10,551 $79.55
2026-08-23 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -5,762 $79.52
2026-08-18 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -100,000 $79.54
2026-08-16 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -52,438 $76.95
2026-08-13 Leonard Post Lead Independent Director Derivative Exercise and Sale -1,000 $0.60–74.54
2026-08-13 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -19,364 $75.02
2026-08-12 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -25,989 $75.95
2026-08-11 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -32,137 $78.62
2026-08-10 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -50,000 $76.21
2026-08-09 Ambaw Bellete Former Chief Operating Officer Intent to Sell (Form 144) -50,000 $75.41

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

CG Oncology discussion 0 comments

Add a comment